Tablet Health lists NAD+ as a treatment on two separate pages and puts no figure on either, while every weight-loss line it sells carries a monthly rate.
What Tablet Health charges
Semaglutide: $199/mo — printed as 'Starting at $199/mo' for compounded injectable semaglutide; its oral semaglutide is listed lower on the same page
Tirzepatide: $299/mo — printed as 'Starting at $299/mo' for compounded injectable tirzepatide; its oral tirzepatide is listed lower on the same page
Tablet Health also sells 1 compound this site boards without publishing a price for it: NAD+.
Tablet Health is not a paid partner; this link may earn a commission if that changes. Full disclosure.
By Nora Castellan, Standards EditorUpdated September 2026
It sells the peptide and prices the other thing
Tablet Health names NAD+ twice, once as an injection and once as a nasal spray, and neither page carries a cost. The peptide is on the menu without a number attached to it.
Every figure the site publishes belongs to its weight-loss line. A reader who arrives for NAD+ finds a treatment description and a route into intake, and nothing that settles what the treatment costs.
That gap is the first thing to know here. The company is willing to print rates elsewhere, so the silence on NAD+ is specific to that line rather than a house policy against publishing prices.
How it writes the figures it does publish
The published rates are marked as monthly and as starting points rather than fixed charges. Both signals sit beside the number, so a reader is told plainly that the figure is a floor.
It also splits oral and injectable versions of the same molecule into separate listings on one page. Sellers frequently blur those two forms into a single advertised rate; this one does not.
What it publishes is a single plan floor rather than a ladder that climbs with each dose step. That makes the entry cost legible and leaves the cost of a higher dose unstated.
Its front door is not its root
Requesting the bare domain does not serve a homepage. The address rewrites to an interior telehealth path on the same host, so the site's actual front door sits one level in.
This is a quirk rather than a defect, but it matters when comparing sellers. The page a reader lands on is a section page, and it is recorded that way here rather than treated as the homepage.
A nonsense address on the same host returns a hard error, so the rewrite is specific to the root rather than a catch-all that answers for anything typed at it.
What it names and what it leaves blank
Tablet LLC appears as the operating company on both the privacy policy and the terms of service. Two legal pages agreeing on one entity is a cleaner answer than much of this roster gives.
Beyond that the disclosures thin out quickly. No page names the pharmacy that fills an order, and no page lists the states the company is able to serve.
Lab work is not described as covered by anything it charges. A buyer should assume bloodwork is a separate cost and settle that during intake.
Who it's for
Buyers shopping the weight-loss line, where every rate is printed and marked monthly.
Readers who want oral and injectable forms of a molecule listed and priced apart.
Anyone who wants the operating company named on more than one legal page.
Shoppers who prefer a single plan floor to a price that climbs with each dose step.
Who should look elsewhere
Anyone shopping for NAD+ on cost, because neither NAD+ page carries a figure.
Buyers who need the dispensing pharmacy named before they order.
Readers who want to confirm their state is served before starting an intake.
People who expect lab work covered by the quoted rate.
Strengths
Marks its GLP-1 figures as monthly and as starting rates rather than flat prices
Separates oral and injectable versions of the same molecule into distinct listings
Names its operating company on two separate legal pages
Publishes a single flat-plan floor rather than a ladder that climbs with dose
Trade-offs
Publishes no figure at all for the peptide it lists, on either NAD+ page
Requesting its bare domain rewrites to an interior path, so its front door is not its root
Publishes no state list and names no dispensing pharmacy
Describes no lab work as included in what it charges
How we verified this
Opened both NAD+ treatment pages, the injection and the nasal spray, and recorded that neither carries a cost of any kind.
Recorded the billing period printed beside each published figure, along with the starting-rate wording attached to it.
Noted where the site lists oral and injectable forms of the same molecule as separate entries on one page.
Requested the bare domain and recorded that it serves an interior path on the same host, with a nonsense address on that host returning a hard error in the same run.
Read the privacy policy and terms of service for the operating company, and searched the public pages for a named pharmacy and a list of states served. Screened the company in the federal warning-letter record with a known-positive and a nonsense control.
A provider to compare Tablet Health against
Trellis Vitality
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
No. It describes NAD+ as an injection on one page and as a nasal spray on another, and neither carries a figure. The prices on this site all belong to its weight-loss line.
Are the published rates fixed?
No. They are written as monthly starting points, which makes each number a floor. A higher dose or a different form may land above it, and the site does not say by how much.
Which pharmacy fills the order?
Tablet Health does not name one. A buyer cannot look up the facility that compounds the medication, so raise it during intake if that would change your decision.
Can it serve my state?
The site publishes no list of states. Eligibility can only be settled once an intake has begun, which means handing over personal details before learning the answer.
Tablet Health is not a paid partner; this link may earn a commission if that changes. Full disclosure.